Clinical trial
A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders
NCT00588991 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 4, 2008
- Completion date
- November 16, 2016
- Enrollment
- 12 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
adult acute megakaryoblastic leukemia, adult acute monoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p21.3;q23.3); mllt3-kmt2a, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, chronic myeloid leukemia, philadelphia chromosome negative, bcr-abl1 positive, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, essential thrombocythemia, hematopoietic and lymphoid cell neoplasm, myelodysplastic syndrome, polycythemia vera, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, secondary myelodysplastic syndrome